Objectives: Neuromyelitis optica (NMO) immunoglobulin G (IgG) (aquaporin-4 [AQP4] IgG) is highly specific for NMO and related disorders, and autoantibody detection has become an essential investigation in patients with demyelinating disease. However, although different techniques are now used, no multicenter comparisons have been performed. This study compares the sensitivity and specificity of different assays, including an in-house flow cytometric assay and 2 commercial assays (ELISA and transfected cell-based assay [CBA]).
Neuromyelitis optica (NMO) is a severe relapsing inflammatory CNS demyelinating disease that predominantly affects the optic nerves and spinal cord. 1 At presentation, the most common differential diagnosis is multiple sclerosis (MS). However, unlike MS, disability in NMO accrues with each attack. Hence, early diagnosis and treatment are critical. 2 The discovery of specific immunoglobulin G (IgG) antibodies binding to CNS astrocytic membranes identified the target as the water channel aquaporin-4 (AQP4), which has aided early recognition of the disease and broadened the clinical spectrum to include patients who have only optic neuritis or transverse myelitis (neuromyelitis optica spectrum disorders [NMOSDs] ). 3, 4 Studies in vitro and in vivo have demonstrated the pathogenic potential of these autoantibodies. [5] [6] [7] [8] [9] [10] However, different assays for detecting AQP4-IgG in patients' sera differ in their sensitivities for NMO and other NMOSDs. 3, 4, [11] [12] [13] [14] [15] [16] [17] In this international multicenter study, 6 different AQP4-IgG assays were compared on coded samples.
METHODS Standard protocol approvals, registrations, and patient consents. This study was approved by all 3 institutional review boards.
Patients. Serum samples from 146 patients and control subjects were tested in duplicate, and 35 patients fulfilled the Wingerchuck diagnostic criteria for NMO (either 1999 or 2006 [excluding antibody status]). 2 Of the patients, 25 were classified by the investigators as having NMOSDs; this group included 14 patients with longitudinally extensive transverse myelitis (9 recurrent) and 8 patients with optic neuritis (5 recurrent; all patients with single attack cases of optic neuritis were seropositive All samples were submitted to McGill University, aliquoted, recoded, and returned frozen to the other 2 centers. Testing at Mayo Clinic included a tissue-based indirect immunofluorescence (IIF) assay for NMO-IgG, 3 ELISA-R (provided by RSR/ Kronus, Ltd.; manufacturer's recommended level for seropositivity, 5 U/mL or greater), and GFP-AQP4 fluorescence immunoprecipitation assay (FIPA-M). 13, 18 Testing at Oxford included a fluorescence immunoprecipitation assay (FIPA-O), 11 visual fluorescence-observation cell-based assay (CBA-O), 11, 18 and a new quantitative flow cytometry (fluorescence-activated cell . Two gates were created: the higher gate captured cells expressing high levels of dsRed (labeled R5 in figure e-1); the lower gate captured untransfected or poorly transfected cells (labeled as R7 in figure e-1) and served as a negative control for each sample. Bound IgG was measured in the green channel (a shift to the right on the x-axis). A score for each serum was determined by subtracting the median green fluorescence in the lower gate from the median green fluorescence in the higher gate.
Statistical analyses.
We used receiver operating characteristic curve (ROC) analysis to identify post hoc the optimal cutoff values for the ELISA-R assay to maximize disease sensitivity and specificity, and analyzed all data using SAS, version 9. A post hoc ROC analysis of ELISA-R raw data revealed that by lowering the cutoff value from 5.0 U/mL to 1.6 U/mL, the sensitivity could be increased from 60% to 70%. An additional 6 of 60 patients with NMO or NMOSD were then scored as Table 1 Sensitivity and specificity of 6 aquaporin- Abbreviations: AUC ϭ area under the curve; CBA ϭ cell-based assay; FACS ϭ fluorescence-activated cell sorting; FIPA ϭ fluorescence immunoprecipitation assay; IgG ϭ immunoglobulin G; IIF ϭ indirect immunofluorescence; M ϭ Mayo; NMO ϭ neuromyelitis optica; NMOSD ϭ neuromyelitis optica spectrum disorder; O ϭ Oxford; R ϭ RSR/Kronus; ROC ϭ receiver operating characteristic curve. a Results for blinded study of 146 samples on 6 assays with calculated sensitivities and specificities. The final column is a measure of assay accuracy. Abbreviations: AUC ϭ area under the curve; E ϭ EUROIMMUN; NMO ϭ neuromyelitis optica; NMOSD ϭ neuromyelitis optica spectrum disorder; R ϭ R ϭ RSR/Kronus; ROC ϭ receiver operating characteristic curve. a A reduction in cutoff from the recommended 5.0 U/mL to 1.6 U/mL improves the ELISA accuracy (demonstrated by an increase in the AUC-ROC score from 0.800 to 0.838). Combining the ELISA kit assay (using a cutoff of 5 U/mL) with CBA-E further improves the sensitivity (AUC-ROC 0.858).
positive ( figure 2A, table 2 ). All 6 were positive by FACS and CBA-O with 5 positive by CBA-E; however, there were also 2 false-positive results (1 healthy control and 1 patient with relapsing-remitting MS). Both of these latter false-positive samples tested negative on both cell-based assays. As a diagnostic assay, the FIPAs were not very sensitive, but they were found to be suitable for serial determinations (figure 2B). Nine sera samples from a single patient taken over 5 years were also tested blinded. The FIPAs showed striking reproducibility between the 2 testing laboratories and a positive correlation between antibody level and treatment response. AQP4-IgG values fell after a single infusion of rituximab (Rituxan) and slowly increased in the following 20 months. A second infusion of rituximab (Rituxan) reduced the AQP4-IgG to an almost undetectable level.
DISCUSSION Sensitive and specific detection of NMO-IgG (AQP4-IgG) has become an essential laboratory investigation in evaluating patients with inflammatory CNS demyelinating disorders, because seropositivity has diagnostic, prognostic, and therapeutic implications. Several different techniques have been used to detect these autoantibodies, and no previous international multicenter comparative study has been performed. In this fully blinded study, we assessed different assays, including a novel in-house FACS method and 2 recent commercially available kit assays (ELISA-R and CBA-E).
The in-house FACS and CBA-O assay proved to be the most sensitive. There was a significant difference in the sensitivity between these assays and the ELISA-R. However, reducing the recommended cutoff for the ELISA-R from 5.0 U/mL to 1.6 U/mL eliminated these significant differences (table 3) but slightly reduced the ELISA-R specificity. The tissuebased IIF assay and FIPA were not optimal for diagnostic assays because of lower sensitivities (48%-53%).
The demand for AQP4-IgG testing is increasing globally. In the past 12 months, the Mayo Clinic's Neuroimmunology Laboratory tested 20,334 patients' sera for AQP4-IgG on a service basis and the Oxford laboratory tested 3,500. The expertise and resources required to perform flow cytometry assays preclude its use in small-scale clinical diagnostic laboratories. This study affirms that commercially available kit assays (ELISA-R and CBA-E) are both sensitive and specific for AQP4-IgG detection. Their relative simplicity to perform, minimal reagent requirement, and amenability to currently available automation platforms allow nonspecialized laboratories to offer sensitive and specific AQP4-IgG testing. This study suggests that CBA-E could be used as a convenient routine assay. The ELISA-R, with the lower cutoff value of 1.6 U/mL, may be a sensitive screening tool, but sera yielding values between 1.6 and 4.9 U/mL would require confirmatory specificity testing by CBA-E.
Comment: Sensitivity and clinical relevance of available anti-aquaporin-4 antibody assays
Anti-aquaporin-4 (AQP4) antibody occurs specifically in neuromyelitis optica (NMO), with various assays able to detect the autoantibody. 1 This international collaborative study compared the sensitivity and specificity of 6 different anti-AQP4 antibody assays, including 2 commercial kits, using coded sera from NMO, NMO spectrum disorders, multiple sclerosis, and control patients. 2 The study was properly done, although it is unclear how the authors selected samples with a wide range of antibody titers, which can substantially influence the sensitivity.
The result was that the specificities were excellent in all assays, but the sensitivities were different. Since anti-AQP4 antibody in NMO is undetectable in Western blot and stains the surface of cells transfected with AQP4, a transmembrane water channel, conformation of the extracellular AQP4 loops appears critically important for the antibody binding. Moreover, the amino acid sequences of extracellular AQP4 domains are somewhat different between humans and rodents. Thus, it was a logical result that human AQP4-transfected cell-based assays in which the antibody binds to the cells in solution were the most sensitive (73%ϳ77%).
The 2 commercial kits suitable to deal with a large number of samples were less sensitive (68% in fixed cell-based assay, and 60% in ELISA), probably because of some nonspecific antibody binding in the fixed cell-based assay and the use of nonmembrane-expressed human AQP4 in ELISA. Lowering the ELISA's cutoff improved the sensitivity, but also produced some false-positives. Manufacturing ELISA with membrane-expressed AQP4 would be desirable. Fluorescence immunoprecipitation assay (FIPA) and the mouse tissue-based immune fluorescence assay were the least sensitive (around 50%), but FIPA seemed useful in antibody titer follow-up.
This study is an important contribution to improve the clinical relevance of this highly specific biomarker for NMO. Although seronegativity does not exclude NMO, anti-AQP4 antibody serologic status has definite and important diagnostic and therapeutic implications, 1 so improving assay sensitivity without sacrificing specificity is crucial. Assay refinement has reduced the frequency of NMO-IgG seronegativity. It is important to determine whether IgG of a different CNS antigen specificity might account for patients with NMOSD who lack detectable AQP4-IgG. An essential prerequisite is to maximize AQP4-IgG assay sensitivity to exclude false negatives. The FACS assay appears to be the most useful in this research context, whereas the FIPA may be more convenient for monitoring patients longitudinally. Functional assays are promising for yielding data to correlate with disease severity and possibly predict relapse.
19

ACKNOWLEDGMENT
The authors thank John Schmeling for performing Mayo Clinic assays and for assistance with data analysis, Kevin Clark for advice with the flow cytometry (WIMM, Oxford), Dr. Klaus-Peter Wandinger and Dr. Christian Probst (EUROIMMUN) for provision of EUROIMMUN CBA slides, and RSR/Kronus for providing AQP4 ELISA-R kits. 
AUTHOR CONTRIBUTIONS
